1
|
Samani AA, Nalbantoglu J, Brodt P. Glioma Cells With Genetically Engineered IGF-I Receptor Downregulation Can Persist in the Brain in a Dormant State. Front Oncol 2020; 10:555945. [PMID: 33072581 PMCID: PMC7539665 DOI: 10.3389/fonc.2020.555945] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2020] [Accepted: 08/24/2020] [Indexed: 11/13/2022] Open
Abstract
Glioblastoma multiforme is an aggressive malignancy, resistant to standard treatment modalities and associated with poor prognosis. We analyzed the role of the IGF system in intracerebral glioma growth using human and rat glioma cells. The glioma cells C6 and U87MG were transduced with a genetically engineered retrovirus expressing type 1 insulin-like growth factor (IGF-IR) antisense RNA, either before or after intra-cerebral implantation of the cells into Sprague Dawley rats or nude mice, respectively and tumor growth and animal survival were monitored. Rat glioma cells transduced prior to orthotopic, intra-cerebral implantation had a significantly increased apoptotic rate in vivo and a significantly reduced tumor volume as seen 24 days post implantation (p < 0.0015). This resulted in increased survival, as greater than 70% of the rats were still alive 182 days after tumor implantation (p < 0.01), as compared to 80% mortality by day 24 in the control group. Histomorphology and histochemical studies performed on brain tissue that was obtained from rats that survived for 182 days revealed numerous single cells that were widely disseminated throughout the brain. These cells expressed the β-galactosidase marker protein, but were Ki67negative, suggesting that they acquired a dormant phenotype. Direct targeting of the C6 cells with retroviral particles in vivo was effective and reduced tumor volumes by 22% relative to controls. A significant effect on tumor growth was also seen with human glioma U87MG cells that were virally transduced and implanted intra-cerebrally in nude mice. We observed in these mice a significant reduction in tumor volumes and 70% of the animals were still alive 6 months after tumor implantation, as compared to 100% mortality in the control group by day 63. Our results show that IGF-IR targeting can inhibit the intracerebral growth of glioma cells. They also suggest that IGF-IR expression levels may determine a delicate balance between glioma cell growth, death and the acquisition of a dormant state in the brain.
Collapse
Affiliation(s)
- Amir A Samani
- Department of Medicine, McGill University, Montreal, QC, Canada
| | - Josephine Nalbantoglu
- Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada
| | - Pnina Brodt
- Department of Medicine, McGill University, Montreal, QC, Canada.,Department of Surgery, McGill University, Montreal, QC, Canada.,Department of Oncology, McGill University, Montreal, QC, Canada.,The Research Institute of the McGill University Health Center, Montreal, QC, Canada
| |
Collapse
|
2
|
Antitumor Activity of DFX117 by Dual Inhibition of c-Met and PI3Kα in Non-Small Cell Lung Cancer. Cancers (Basel) 2019; 11:cancers11050627. [PMID: 31060329 PMCID: PMC6562471 DOI: 10.3390/cancers11050627] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2019] [Revised: 04/26/2019] [Accepted: 05/01/2019] [Indexed: 02/07/2023] Open
Abstract
Aberrant activation of hepatocyte growth factor (HGF)/c-Met signaling pathway caused by gene amplification or mutation plays an important role in tumorigenesis. Therefore, c-Met is considered as an attractive target for cancer therapy and c-Met inhibitors have been developed with great interests. However, cancers treated with c-Met inhibitors inevitably develop resistance commonly caused by the activation of PI3K/Akt signal transduction pathway. Therefore, the combination of c-Met and PI3Kα inhibitors showed synergistic activities, especially, in c-Met hyperactivated and PIK3CA-mutated cells. In our previous study, we rationally designed and synthesized DFX117(6-(5-(2,4-difluorophenylsulfonamido)-6-methoxypyridin-3-yl)-N-(2-morpholinoethyl) imidazo[1,2-a]pyridine-3-carboxamide) as a novel PI3Kα selective inhibitor. Herein, the antitumor activity and underlying mechanisms of DFX117 against non-small cell lung cancer (NSCLC) cells were evaluated in both in vitro and in vivo animal models. Concurrent targeted c-Met and PI3Kα by DFX117 dose-dependent inhibited the cell growth of H1975 cells (PIK3CA mutation and c-Met amplification) and A549 cells (KRAS mutation). DFX117 subsequently induced G0/G1 cell cycle arrest and apoptosis. These data highlight the significant potential of DFX117 as a feasible and efficacious agent for the treatment of NSCLC patients.
Collapse
|
3
|
Tung B, Ma D, Wang S, Oyinlade O, Laterra J, Ying M, Lv SQ, Wei S, Xia S. Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells. BMC Cancer 2018; 18:1025. [PMID: 30348136 PMCID: PMC6198521 DOI: 10.1186/s12885-018-4874-8] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2018] [Accepted: 09/28/2018] [Indexed: 12/30/2022] Open
Abstract
Background The dismal prognosis of patients with glioblastoma (GBM) is attributed to a rare subset of cancer stem cells that display characteristics of tumor initiation, growth, and resistance to aggressive treatment involving chemotherapy and concomitant radiation. Recent research on the substantial role of epigenetic mechanisms in the pathogenesis of cancers has prompted the investigation of the enzymatic modifications of histone proteins for therapeutic drug targeting. In this work, we have examined the function of Krüppel-like factor 9 (KLF9), a transcription factor, in chemotherapy sensitization to histone deacetylase inhibitors (HDAC inhibitors). Methods Since GBM neurosphere cultures from patient-derived gliomas are enriched for GBM stem-like cells (GSCs) and form highly invasive and proliferative xenografts that recapitulate the features demonstrated in human patients diagnosed with GBM, we established inducible KLF9 expression systems in these GBM neurosphere cells and investigated cell death in the presence of epigenetic modulators such as histone deacetylase (HDAC) inhibitors. Results We demonstrated that KLF9 expression combined with HDAC inhibitor panobinostat (LBH589) dramatically induced glioma stem cell death via both apoptosis and necroptosis in a synergistic manner. The combination of KLF9 expression and LBH589 treatment affected cell cycle by substantially decreasing the percentage of cells at S-phase. This phenomenon is further corroborated by the upregulation of cell cycle inhibitors p21 and p27. Further, we determined that KLF9 and LBH589 regulated the expression of pro- and anti- apoptotic proteins, suggesting a mechanism that involves the caspase-dependent apoptotic pathway. In addition, we demonstrated that apoptosis and necrosis inhibitors conferred minimal protective effects against cell death, while inhibitors of the necroptosis pathway significantly blocked cell death. Conclusions Our findings suggest a detailed understanding of how KLF9 expression in cancer cells with epigenetic modulators like HDAC inhibitors may promote synergistic cell death through a mechanism involving both apoptosis and necroptosis that will benefit novel combinatory antitumor strategies to treat malignant brain tumors.
Collapse
Affiliation(s)
- Brian Tung
- Hugo W. Moser Research Institute at Kennedy Krieger, The Johns Hopkins School of Medicine, 707 N. Broadway, Room 400K, Baltimore, MD, 21205, USA
| | - Ding Ma
- Hugo W. Moser Research Institute at Kennedy Krieger, The Johns Hopkins School of Medicine, 707 N. Broadway, Room 400K, Baltimore, MD, 21205, USA.,Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - Shuyan Wang
- Hugo W. Moser Research Institute at Kennedy Krieger, The Johns Hopkins School of Medicine, 707 N. Broadway, Room 400K, Baltimore, MD, 21205, USA.,Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - Olutobi Oyinlade
- Hugo W. Moser Research Institute at Kennedy Krieger, The Johns Hopkins School of Medicine, 707 N. Broadway, Room 400K, Baltimore, MD, 21205, USA.,Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - John Laterra
- Hugo W. Moser Research Institute at Kennedy Krieger, The Johns Hopkins School of Medicine, 707 N. Broadway, Room 400K, Baltimore, MD, 21205, USA.,Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.,Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.,Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - Mingyao Ying
- Hugo W. Moser Research Institute at Kennedy Krieger, The Johns Hopkins School of Medicine, 707 N. Broadway, Room 400K, Baltimore, MD, 21205, USA.,Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - Sheng-Qing Lv
- Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China
| | - Shuang Wei
- Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, 430030, China
| | - Shuli Xia
- Hugo W. Moser Research Institute at Kennedy Krieger, The Johns Hopkins School of Medicine, 707 N. Broadway, Room 400K, Baltimore, MD, 21205, USA. .,Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
| |
Collapse
|
4
|
Oyinlade O, Wei S, Kammers K, Liu S, Wang S, Ma D, Huang ZY, Qian J, Zhu H, Wan J, Xia S. Analysis of KLF4 regulated genes in cancer cells reveals a role of DNA methylation in promoter- enhancer interactions. Epigenetics 2018; 13:751-768. [PMID: 30058478 DOI: 10.1080/15592294.2018.1504592] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Recent studies have revealed an unexpected role of DNA methylation at promoter regions in transcription activation. However, whether DNA methylation at enhancer regions activates gene expression and influences cellular functions remains to be determined. In this study, by employing the transcription factor krÜppel-like factor 4 (KLF4) that binds to methylated CpGs (mCpGs), we investigated the molecular outcomes of the recruitment of KLF4 to mCpGs at enhancer regions in human glioblastoma cells. First, by integrating KLF4 ChIP-seq, whole-genome bisulfite sequence, and H3K27ac ChIP-seq datasets, we found 1,299 highly methylated (β >0.5) KLF4 binding sites, three-quarters of which were located at putative enhancer regions, including gene bodies and intergenic regions. In the meantime, by proteomics, we identified 16 proteins as putative targets upregulated by KLF4-mCpG binding at enhancer regions. By chromosome conformation capture (3C) analysis, we demonstrated that KLF4 bound to methylated CpGs at the enhancer regions of the B-cell lymphocyte kinase (BLK) and Lim domain only protein 7 (LMO7) genes, and activated their expression via 3D chromatin loop formation with their promoter regions. Expression of mutant KLF4, which lacks KLF4 ability to bind methylated DNA, or removal of DNA methylation in enhancer regions by a DNA methyltransferase inhibitor abolished chromatin loop formation and gene expression, suggesting the essential role of DNA methylation in enhancer-promoter interactions. Finally, we performed functional assays and showed that BLK was involved in glioblastoma cell migration. Together, our study established the concept that DNA methylation at enhancer regions interacts with transcription factors to activate gene expression and influence cellular functions.
Collapse
Affiliation(s)
- Olutobi Oyinlade
- a Hugo W. Moser Research Institute at Kennedy Krieger , Baltimore , Maryland , USA.,b Department of Pharmacology and Molecular Sciences , Johns Hopkins School of Medicine, Johns Hopkins University , Baltimore , Maryland , USA
| | - Shuang Wei
- a Hugo W. Moser Research Institute at Kennedy Krieger , Baltimore , Maryland , USA.,c Department of Neurology , Johns Hopkins School of Medicine, Johns Hopkins University , Baltimore , Maryland , USA.,g Department of Respiratory and Critical Care Medicine, Tongji Hospital , Tongji Medical College Huazhong University of Science and Technology , Wuhan , China
| | - Kai Kammers
- d Division of Biostatistics and Bioinformatics,Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine , Johns Hopkins University , Baltimore , Maryland , USA
| | - Sheng Liu
- i Department of Medical and Molecular Genetics , Indiana University School of Medicine , Indianapolis , IN , USA
| | - Shuyan Wang
- a Hugo W. Moser Research Institute at Kennedy Krieger , Baltimore , Maryland , USA.,c Department of Neurology , Johns Hopkins School of Medicine, Johns Hopkins University , Baltimore , Maryland , USA
| | - Ding Ma
- a Hugo W. Moser Research Institute at Kennedy Krieger , Baltimore , Maryland , USA.,c Department of Neurology , Johns Hopkins School of Medicine, Johns Hopkins University , Baltimore , Maryland , USA
| | - Zhi-Yong Huang
- h Department of General Surgery, Tongji Hospital , Tongji Medical College Huazhong University of Science and Technology , Wuhan , China
| | - Jiang Qian
- e Wilmer Eye Institute,Johns Hopkins School of Medicine , Johns Hopkins University , Baltimore , Maryland , USA
| | - Heng Zhu
- b Department of Pharmacology and Molecular Sciences , Johns Hopkins School of Medicine, Johns Hopkins University , Baltimore , Maryland , USA.,f Center for High Throughput Biology, Johns Hopkins School of Medicine , Johns Hopkins University , Baltimore , Maryland , USA
| | - Jun Wan
- i Department of Medical and Molecular Genetics , Indiana University School of Medicine , Indianapolis , IN , USA.,j Center for Computational Biology and Bioinformatics , Indiana University School of Medicine , Indianapolis , IN , USA
| | - Shuli Xia
- a Hugo W. Moser Research Institute at Kennedy Krieger , Baltimore , Maryland , USA.,c Department of Neurology , Johns Hopkins School of Medicine, Johns Hopkins University , Baltimore , Maryland , USA
| |
Collapse
|
5
|
Wang W, Tang L, Li Q, Tan J, Yao H, Duan Z, Xia X. Overexpression of miR-31-5p inhibits human chordoma cells proliferation and invasion by targeting the oncogene c-Met through suppression of AKT/PI3K signaling pathway. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 2017; 10:8000-8009. [PMID: 31966652 PMCID: PMC6965250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 01/20/2017] [Accepted: 02/23/2017] [Indexed: 06/10/2023]
Abstract
Altered microRNA (miRNAs) expression has been reported in chordoma which has been considered as an important and complex disease. The study aims to explore the mechanism of miR-31-5p in chordoma in vitro. We firstly verified miR-31-5p level after mimics transfection using real-time PCR and found over-expressed miR-31-5p could inhibit cell growth and invasive ability, while induce cell apoptosis in vitro as detected by CCK8 assay, flow cytometry assay and transwell assay, respectively. Based on prediction result in silico, we validated the target gene C-met using dual-luciferase assay and detected the alternation of miR-31-5p as evidence. Using recombinant plasmid, we also found over-expressed c-Met could reduce the effect of over-expressed miR-31-5p on cell growth, cell cycle change, cell apoptosis and invasive ability as detected by CCK8 assay, flow cytometry assay and transwell assay respectively. Meanwhile, it was also appeared that the PI3K/AKT signaling pathway relevant proteins had alternation through WB assays in U-CH1 cells with treatment of miR-31-5p and c-met recombinant plasmid. miR-31-5p may play a protective role in chordoma patients by targeting c-met and then activating PI3K/AKT signaling pathway which suggested that alterations of miR-31-5p might be a useful biomarker and a potential therapy for early detection of chordoma as disease-related molecular and genetic changes.
Collapse
Affiliation(s)
- Wenbo Wang
- Department of Neurosurgery, Guilin Medical University, Affiliated HospitalGuilin, Guangxi, People’s Republic of China
- Laboratory of Medical Neurobiology, Guilin Medical UniversityGuilin, Guangxi, People’s Republic of China
| | - Lejian Tang
- Department of Neurosurgery, Guilin Medical University, Affiliated HospitalGuilin, Guangxi, People’s Republic of China
| | - Qinghua Li
- Laboratory of Medical Neurobiology, Guilin Medical UniversityGuilin, Guangxi, People’s Republic of China
| | - Jie Tan
- Laboratory of Medical Neurobiology, Guilin Medical UniversityGuilin, Guangxi, People’s Republic of China
| | - Hanxun Yao
- Department of Neurosurgery, Guilin Medical University, Affiliated HospitalGuilin, Guangxi, People’s Republic of China
| | - Zhengying Duan
- Department of Neurosurgery, Guilin Medical University, Affiliated HospitalGuilin, Guangxi, People’s Republic of China
| | - Xuewei Xia
- Department of Neurosurgery, Guilin Medical University, Affiliated HospitalGuilin, Guangxi, People’s Republic of China
- Laboratory of Medical Neurobiology, Guilin Medical UniversityGuilin, Guangxi, People’s Republic of China
| |
Collapse
|
6
|
Ding K, Wu Z, Wang N, Wang X, Wang Y, Qian P, Meng G, Tan S. MiR-26a performs converse roles in proliferation and metastasis of different gastric cancer cells via regulating of PTEN expression. Pathol Res Pract 2017; 213:467-475. [PMID: 28242043 DOI: 10.1016/j.prp.2017.01.026] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/24/2016] [Revised: 01/23/2017] [Accepted: 01/23/2017] [Indexed: 12/12/2022]
Abstract
Gastric cancer is the second leading cause of cancer-related death in the world. The exact molecular pathways in gastric cancer need for further study. We herein indicated miR-26a performed converse roles on oncogenicity in different gastric cancer cells. In gastric cancer cells MKN-28, miR-26a promoted cell proliferation, migration and invasion. However, in gastric cancer cells AGS, miR-26a reduced cell proliferation and metastasis. PTEN was identified as a direct target of miR-26a. In MKN-28 cells, PTEN was suppressed by miR-26a through 3'-UTR, and PTEN mediated miR-26a promoting oncogenicity including cell proliferation and metastasis. On the other hand, in AGS cells, the expression of PTEN was enhanced by miR-26a, and PTEN mediated miR-26a reducing oncogenicity. The mechanism in AGS cells may be the indirect regulation of PTEN by miR-26a overcame the direct targeting regulation. The model like MKN-28 cells was concordant with patients with a high level of miR-26a and a low level of PTEN and patients with a low level of miR-26a and a high level of PTEN which showed lower overall survival (OS); the model like AGS cells was concordant with patients with both high level of miR-26a and PTEN and both low level of miR-26a and PTEN which showed higher OS. These findings will facilitate a better understanding of the functions and mechanisms about miR-26a, miR-26a and PTEN are potential combined biomarkers in patients with gastric cancer.
Collapse
Affiliation(s)
- Keshuo Ding
- Department of Pathology, Anhui Medical University, Hefei, Anhui, People's Republic of China
| | - Zhengsheng Wu
- Department of Pathology, Anhui Medical University, Hefei, Anhui, People's Republic of China
| | - Nana Wang
- Department of Pathology, Anhui Medical University, Hefei, Anhui, People's Republic of China; Department of Pathology, The Fourth Affiliated Hospital of Anhui Medical University, People's Republic of China
| | - Xiaonan Wang
- Laboratory of Pathogenic Microbiology and Immunology, Anhui Medical University, Hefei, Anhui, People's Republic of China
| | - Yuejun Wang
- Department of Pathology, Anhui Medical University, Hefei, Anhui, People's Republic of China; Department of Pathology, The Fourth Affiliated Hospital of Anhui Medical University, People's Republic of China
| | - Pengxu Qian
- Laboratory of Molecular Tumor Pathology, School of Life Science, University of Science and Technology of China, Hefei, Anhui, People's Republic of China
| | - Gang Meng
- Department of Pathology, Anhui Medical University, Hefei, Anhui, People's Republic of China.
| | - Sheng Tan
- Laboratory of Molecular Tumor Pathology, School of Life Science, University of Science and Technology of China, Hefei, Anhui, People's Republic of China.
| |
Collapse
|
7
|
Microarray-Based Phospho-Proteomic Profiling of Complex Biological Systems. Transl Oncol 2016; 9:124-129. [PMID: 27084428 PMCID: PMC4833893 DOI: 10.1016/j.tranon.2016.02.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2015] [Revised: 02/16/2016] [Accepted: 02/17/2016] [Indexed: 01/29/2023] Open
Abstract
Protein microarray technology has been successfully used for identifying substrates of purified activated kinases. We used protein microarrays to globally interrogate the effects of PTEN and Akt activity on the phospho-kinome of in vitro and in vivo glioma models and validated results in clinical pathological specimens. Whole cell lysates extracted from tumor samples can be applied to human kinome chip microarrays to profile the global kinase phosphorylation patterns in a high-throughput manner and identify novel substrates inherent to the tumor cell and the interactions with tumor microenvironment. Our findings identify a novel microarray-based method for assessing intracellular signaling events applicable to human oncogenesis and other pathophysiologic states.
Collapse
|
8
|
Kim SH, Ezhilarasan R, Phillips E, Gallego-Perez D, Sparks A, Taylor D, Ladner K, Furuta T, Sabit H, Chhipa R, Cho JH, Mohyeldin A, Beck S, Kurozumi K, Kuroiwa T, Iwata R, Asai A, Kim J, Sulman EP, Cheng SY, Lee LJ, Nakada M, Guttridge D, DasGupta B, Goidts V, Bhat KP, Nakano I. Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent Manner. Cancer Cell 2016; 29:201-13. [PMID: 26859459 PMCID: PMC4837946 DOI: 10.1016/j.ccell.2016.01.005] [Citation(s) in RCA: 122] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/27/2014] [Revised: 06/26/2015] [Accepted: 01/11/2016] [Indexed: 12/24/2022]
Abstract
Activation of nuclear factor κB (NF-κB) induces mesenchymal (MES) transdifferentiation and radioresistance in glioma stem cells (GSCs), but molecular mechanisms for NF-κB activation in GSCs are currently unknown. Here, we report that mixed lineage kinase 4 (MLK4) is overexpressed in MES but not proneural (PN) GSCs. Silencing MLK4 suppresses self-renewal, motility, tumorigenesis, and radioresistance of MES GSCs via a loss of the MES signature. MLK4 binds and phosphorylates the NF-κB regulator IKKα, leading to activation of NF-κB signaling in GSCs. MLK4 expression is inversely correlated with patient prognosis in MES, but not PN high-grade gliomas. Collectively, our results uncover MLK4 as an upstream regulator of NF-κB signaling and a potential molecular target for the MES subtype of glioblastomas.
Collapse
Affiliation(s)
- Sung-Hak Kim
- Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | - Ravesanker Ezhilarasan
- Department of Radiation Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA
| | - Emma Phillips
- Division of Molecular Genetics, German Cancer Research Center, 69120 Heidelberg, Germany
| | - Daniel Gallego-Perez
- Department of Surgery, The Ohio State University, Columbus, OH 43210, USA; Department of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA; Center for Affordable Nanoengineering of Polymeric Biomedical Devices, The Ohio State University, Columbus, OH 43210, USA; Center for Regenerative Medicine and Cell-Based Therapies, The Ohio State University, Columbus, OH 43210, USA
| | - Amanda Sparks
- Department of Neurosurgery, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
| | - David Taylor
- Department of Neurosurgery, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
| | - Katherine Ladner
- Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA
| | - Takuya Furuta
- Department of Neurosurgery, Kanazawa University, Kanazawa 920-8641, Japan
| | - Hemragul Sabit
- Department of Neurosurgery, Kanazawa University, Kanazawa 920-8641, Japan
| | - Rishi Chhipa
- Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45242, USA
| | - Ju Hwan Cho
- Department of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
| | - Ahmed Mohyeldin
- Department of Neurosurgery, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
| | - Samuel Beck
- Department of Molecular Biosciences, Institute for Cellular and Molecular Biology, Center for Systems and Synthetic Biology, The University of Texas at Austin, Austin, TX 78712, USA
| | - Kazuhiko Kurozumi
- Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan
| | - Toshihiko Kuroiwa
- Department of Neurosurgery, Osaka Medical College, Osaka 569-8686, Japan
| | - Ryoichi Iwata
- Department of Neurosurgery, Kansai Medical University, Osaka 573-1191, Japan
| | - Akio Asai
- Department of Neurosurgery, Kansai Medical University, Osaka 573-1191, Japan
| | - Jonghwan Kim
- Department of Molecular Biosciences, Institute for Cellular and Molecular Biology, Center for Systems and Synthetic Biology, The University of Texas at Austin, Austin, TX 78712, USA
| | - Erik P Sulman
- Department of Radiation Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA
| | - Shi-Yuan Cheng
- The Ken & Ruth Davee Department of Neurology & Northwestern Brain Tumor Institute, Center for Genetic Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - L James Lee
- Center for Affordable Nanoengineering of Polymeric Biomedical Devices, The Ohio State University, Columbus, OH 43210, USA; Center for Regenerative Medicine and Cell-Based Therapies, The Ohio State University, Columbus, OH 43210, USA; Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH 43210, USA
| | - Mitsutoshi Nakada
- Department of Neurosurgery, Kanazawa University, Kanazawa 920-8641, Japan
| | - Denis Guttridge
- Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA
| | - Biplab DasGupta
- Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45242, USA
| | - Violaine Goidts
- Division of Molecular Genetics, German Cancer Research Center, 69120 Heidelberg, Germany
| | - Krishna P Bhat
- Department of Translational Molecular Pathology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA
| | - Ichiro Nakano
- Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA; UAB Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
| |
Collapse
|
9
|
Sun H, Luo L, Lal B, Ma X, Chen L, Hann CL, Fulton AM, Leahy DJ, Laterra J, Li M. A monoclonal antibody against KCNK9 K(+) channel extracellular domain inhibits tumour growth and metastasis. Nat Commun 2016; 7:10339. [PMID: 26842342 PMCID: PMC4742836 DOI: 10.1038/ncomms10339] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2015] [Accepted: 11/30/2015] [Indexed: 12/25/2022] Open
Abstract
Two-pore domain potassium (K2P) channels act to maintain cell resting membrane potential--a prerequisite for many biological processes. KCNK9, a member of K2P family, is implicated in cancer, owing to its overexpression in human tumours and its ability to promote neoplastic cell survival and growth. However, KCNK9's underlying contributions to malignancy remain elusive due to the absence of specific modulators. Here we describe the development of monoclonal antibodies against the KCNK9 extracellular domain and their functional effects. We show that one antibody (Y4) with the highest affinity binding induces channel internalization. The addition of Y4 to KCNK9-expressing carcinoma cells reduces cell viability and increases cell death. Systemic administration of Y4 effectively inhibits growth of human lung cancer xenografts and murine breast cancer metastasis in mice. Evidence for Y4-mediated carcinoma cell autonomous and immune-dependent cytotoxicity is presented. Our study reveals that antibody-based KCNK9 targeting is a promising therapeutic strategy in KCNK9-expressing malignancies.
Collapse
Affiliation(s)
- Han Sun
- Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.,Hugo W. Moser Research Institute at Kennedy Krieger, Baltimore, Maryland 21205, USA
| | - Liqun Luo
- Immunotherapy Institute, Fujian Medical University, Fujian 350108, China
| | - Bachchu Lal
- Hugo W. Moser Research Institute at Kennedy Krieger, Baltimore, Maryland 21205, USA
| | - Xinrong Ma
- Department of Pathology, University of Maryland, Baltimore, Maryland 21201, USA
| | - Lieping Chen
- Department of Immunobiology and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06511, USA
| | - Christine L Hann
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
| | - Amy M Fulton
- Department of Pathology, University of Maryland, Baltimore, Maryland 21201, USA.,Baltimore Veterans Administration Medical Center, Baltimore, Maryland 21201, USA
| | - Daniel J Leahy
- Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
| | - John Laterra
- Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.,Hugo W. Moser Research Institute at Kennedy Krieger, Baltimore, Maryland 21205, USA.,Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.,Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
| | - Min Li
- Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
| |
Collapse
|
10
|
Zhao Y, Sun Y, Zhang H, Liu X, Du W, Li Y, Zhang J, Chen L, Jiang C. HGF/MET signaling promotes glioma growth via up-regulation of Cox-2 expression and PGE2 production. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 2015; 8:3719-3726. [PMID: 26097553 PMCID: PMC4466940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 01/20/2015] [Accepted: 03/20/2015] [Indexed: 06/04/2023]
Abstract
Cyclooxygenase2 (Cox-2) is well known for glioma growth through up-regulation of prostaglandin E2 (PGE2) levels. MET, a hepatocyte growth factor (HGF) receptor, is also frequently high expressed in glioma, which promotes glioma growth and invasion. Here, we demonstrate that HGF/MET signaling can promote PGE2 production in glioma cells via Cox-2 up-regulation. RNA inhibition of MET suggested that MET signaling is essential for Cox-2 up-regulation. Moreover, HGF could enhance Cox-2 expression and PGE2 release. Knockdown of Cox-2 inhibited growth-promoting effects of HGF, suggesting that HGF/MET functioned via Cox-2/PGE2 pathway. Therefore, our work reveals a critical relationship of Cox-2/PGE2 and HGF/MET signaling in promoting glioma cells proliferation. Further, targeting MET and Cox-2 may represent an attractive target therapy for glioma.
Collapse
Affiliation(s)
- Yan Zhao
- Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical UniversityHarbin 150086, China
| | - Ying Sun
- Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical UniversityHarbin 150086, China
| | - Haiyan Zhang
- Department of Obstetrics and Gynecology, International Peace Maternal and Children’s Hospital, Shanghai Jiaotong UniversityShanghai, China
| | - Xing Liu
- Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical UniversityHarbin 150086, China
| | - Wenzong Du
- Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical UniversityHarbin 150086, China
| | - Yongli Li
- Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical UniversityHarbin 150086, China
| | - Junhe Zhang
- Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical UniversityHarbin 150086, China
| | - Lingchao Chen
- Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical UniversityHarbin 150086, China
- Department of Neurosurgery, Huashan Hospital, Fudan UniversityShanghai 200040, China
| | - Chuanlu Jiang
- Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical UniversityHarbin 150086, China
| |
Collapse
|
11
|
Extracellular vesicles in the biology of brain tumour stem cells--Implications for inter-cellular communication, therapy and biomarker development. Semin Cell Dev Biol 2015; 40:17-26. [PMID: 25721810 DOI: 10.1016/j.semcdb.2015.02.011] [Citation(s) in RCA: 78] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2014] [Revised: 02/17/2015] [Accepted: 02/17/2015] [Indexed: 12/14/2022]
Abstract
Extracellular vesicles (EVs) act as carriers of molecular and oncogenic signatures present in subsets of tumour cells and tumour-associated stroma, and as mediators of intercellular communication. These processes likely involve cancer stem cells (CSCs). EVs represent a unique pathway of cellular export and cell-to-cell transfer of insoluble molecular regulators such as membrane receptors, signalling proteins and metabolites, thereby influencing the functional integration of cancer cell populations. While mechanisms that control biogenesis, cargo and uptake of different classes of EVs (exosomes, microvesicles, ectosomes, large oncosomes) are poorly understood, they likely remain under the influence of stress-responses, microenvironment and oncogenic processes that define the biology and heterogeneity of human cancers. In glioblastoma (GBM), recent molecular profiling approaches distinguished several disease subtypes driven by distinct molecular, epigenetic and mutational mechanisms, leading to formation of proneural, neural, classical and mesenchymal tumours. Moreover, molecularly distinct clonal cellular lineages co-exist within individual GBM lesions, where they differentiate according to distinct stem cell hierarchies resulting in several facets of tumour heterogeneity and the related potential for intercellular interactions. Glioma stem cells (GSCs) may carry signatures of either proneural or mesenchymal GBM subtypes and differ in several biological characteristics that are, at least in part, represented by the output and repertoire of EV production (vesiculome). We report that vesiculomes differ between known GBM subtypes. EVs may also reflect and influence the equilibrium of the stem cell hierarchy, contain oncogenic drivers and modulate the microenvironment (vascular niche). The GBM/GSC subtype-specific differentials in EV cargo of proteins, transcripts, microRNA and DNA may enable detection of the dynamics of the stem cell compartment and result in biological effects that remain to be fully characterized.
Collapse
|
12
|
Yang TS, Yang XH, Chen X, Wang XD, Hua J, Zhou DL, Zhou B, Song ZS. MicroRNA-106b in cancer-associated fibroblasts from gastric cancer promotes cell migration and invasion by targeting PTEN. FEBS Lett 2014; 588:2162-9. [PMID: 24842611 DOI: 10.1016/j.febslet.2014.04.050] [Citation(s) in RCA: 81] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2014] [Revised: 04/02/2014] [Accepted: 04/13/2014] [Indexed: 12/20/2022]
Abstract
It is well established that the interaction between cancer cells and microenvironment has a critical role in tumor development, but the roles of miRNAs in this interaction are rarely known. Here, we have shown that miR-106b is up-regulated in cancer associated fibroblasts compared with normal fibroblasts established from patients with gastric cancer, the expression level of miR-106b is associated with poor prognosis of patients, and CAFs with down-regulated miR-106b could significantly inhibit gastric cancer cell migration and invasion by targeting PTEN. Taken together, these data suggest that miR-106b might be a novel candidate target for the treatment of gastric cancer.
Collapse
Affiliation(s)
- Ting-Song Yang
- Department of General Surgery, Tenth Peoples' Hospital, School of Medicine, Tongji University, 301 Middle Yanchang Road, Shanghai 200072, China.
| | - Xiao-Hu Yang
- Department of General Surgery, Tenth Peoples' Hospital, School of Medicine, Tongji University, 301 Middle Yanchang Road, Shanghai 200072, China.
| | - Xi Chen
- Department of General Surgery, Tenth Peoples' Hospital, School of Medicine, Tongji University, 301 Middle Yanchang Road, Shanghai 200072, China.
| | - Xu-Dong Wang
- Department of General Surgery, Tenth Peoples' Hospital, School of Medicine, Tongji University, 301 Middle Yanchang Road, Shanghai 200072, China.
| | - Jie Hua
- Department of General Surgery, Tenth Peoples' Hospital, School of Medicine, Tongji University, 301 Middle Yanchang Road, Shanghai 200072, China.
| | - Dong-Lei Zhou
- Department of General Surgery, Tenth Peoples' Hospital, School of Medicine, Tongji University, 301 Middle Yanchang Road, Shanghai 200072, China.
| | - Bo Zhou
- Department of General Surgery, Tenth Peoples' Hospital, School of Medicine, Tongji University, 301 Middle Yanchang Road, Shanghai 200072, China.
| | - Zhen-Shun Song
- Department of General Surgery, Tenth Peoples' Hospital, School of Medicine, Tongji University, 301 Middle Yanchang Road, Shanghai 200072, China.
| |
Collapse
|